Long non-coding RNA TINCR as potential biomarker and therapeutic target for cancer

Sharma, Uttam; Barwal, Tushar Singh; Malhotra, Akshay; Pant, Neha; Vivek, .; Dey, Damayanti; Gautam, Ashima; Tuli, Hardeep Singh; Vásquez, Karen M.; Jain, Aklank

doi:10.1016/j.lfs.2020.118035

Cited by 54 publications

(43 citation statements)

References 87 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tissue Differentiation-Induced Non-Coding RNA TINCR is highly expressed in keratinocytes and is essential for normal epidermal differentiation (206). It is a 3,733-nucleotide long transcript located on chromosome 19p13 (207). Aberrant TINCR expression has been implicated in multiple human cancers.…”

Section: Colon Cancer Associated Transcriptmentioning

confidence: 99%

Long Non-Coding RNAs as Potential Diagnostic and Prognostic Biomarkers in Breast Cancer: Progress and Prospects

Wei

Zhang

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

Breast cancer is the most common malignancy among women worldwide, excluding non-melanoma skin cancer. It is now well understood that breast cancer is a heterogeneous entity that exhibits distinctive histological and biological features, treatment responses and prognostic patterns. Therefore, the identification of novel ideal diagnostic and prognostic biomarkers is of utmost importance. Long non-coding RNAs (lncRNAs) are commonly defined as transcripts longer than 200 nucleotides that lack coding potential. Extensive research has shown that lncRNAs are involved in multiple human cancers, including breast cancer. LncRNAs with dysregulated expression can act as oncogenes or tumor-suppressor genes to regulate malignant transformation processes, such as proliferation, invasion, migration and drug resistance. Intriguingly, the expression profiles of lncRNAs tend to be highly cell-type-specific, tissue-specific, disease-specific or developmental stage-specific, which makes them suitable biomarkers for breast cancer diagnosis and prognosis.

show abstract

Section: Colon Cancer Associated Transcriptmentioning

confidence: 99%

Long Non-Coding RNAs as Potential Diagnostic and Prognostic Biomarkers in Breast Cancer: Progress and Prospects

Wei

Zhang

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Long noncoding RNAs (lncRNAs) are a subtype of ncRNAs that are >200 nucleotides in length [ 13 , 14 , 61 , 62 , 63 ], and several have been implicated in the development and progression of breast cancer [ 31 ]. LncRNAs can act as promoters or suppressors during breast cancer progression via molecular mechanisms that include modulating cellular proliferation, invasion, apoptosis, and drug resistance [ 12 , 14 ].…”

Section: Noncoding Rnas (Mirnas and Lncrna) And Their Aberrant Expression In Er-positive Breast Cancermentioning

confidence: 99%

MicroRNAs and Long Noncoding RNAs as Novel Therapeutic Targets in Estrogen Receptor-Positive Breast and Ovarian Cancers

Barwal

Sharma

Bazala

et al. 2021

IJMS

Self Cite

View full text Add to dashboard Cite

Aromatase inhibitors (AIs) such as anastrozole, letrozole, and exemestane have shown to prevent metastasis and angiogenesis in estrogen receptor (ER)-positive breast and ovarian tumors. They function primarily by reducing estrogen production in ER-positive post-menopausal breast and ovarian cancer patients. Unfortunately, current AI-based therapies often have detrimental side-effects, along with acquired resistance, with increased cancer recurrence. Thus, there is an urgent need to identify novel AIs with fewer side effects and improved therapeutic efficacies. In this regard, we and others have recently suggested noncoding RNAs (ncRNAs), specifically microRNAs (miRNAs) and long noncoding RNAs (lncRNAs), as potential molecular targets for utilization in modulating cancer hallmarks and overcoming drug resistance in several cancers, including ER-positive breast and ovarian cancer. Herein, we describe the disruptive functions of several miRNAs and lncRNAs seen in dysregulated cancer metabolism, with a focus on the gene encoding for aromatase (CYP19A1 gene) and estrogen synthesis as a novel therapeutic approach for treating ER-positive breast and ovarian cancers. Furthermore, we discuss the oncogenic and tumor-suppressive roles of several miRNAs (oncogenic miRNAs: MIR125b, MIR155, MIR221/222, MIR128, MIR2052HG, and MIR224; tumor-suppressive miRNAs: Lethal-7f, MIR27B, MIR378, and MIR98) and an oncogenic lncRNA (MIR2052HG) in aromatase-dependent cancers via transcriptional regulation of the CYP19A1 gene. Additionally, we discuss the potential effects of dysregulated miRNAs and lncRNAs on the regulation of critical oncogenic molecules, such as signal transducer, and activator of transcription 3, β-catenin, and integrins. The overall goal of this review is to stimulate further research in this area and to facilitate the development of ncRNA-based approaches for more efficacious treatments of ER-positive breast and ovarian cancer patients, with a slight emphasis on associated treatment–delivery mechanisms.

show abstract

“…Long non-coding ribonucleic acids (RNAs) (lncRNAs), which consist of more than 200 nucleotides, are involved in protein translation and messenger RNA (mRNA) decay, which play important roles in regulating inflammatory pathways (16,17). A growing number of studies has revealed that some lncRNAs participate in the pathogenesis of multiple diseases, including cancer, ocular alkali burns, and Sjögren's syndrome by regulating mRNA directly or indirectly (18)(19)(20). Long non-coding ribonucleic acids regulate gene expression through epigenetic regulation, transcriptional regulation, and post-transcriptional regulation, thus participating in various biological processes (BP) such as cell proliferation, differentiation, and apoptosis (21)(22)(23)(24)(25)(26).…”

Section: Introductionmentioning

confidence: 99%

Long Non-coding RNAs Gabarapl2 and Chrnb2 Positively Regulate Inflammatory Signaling in a Mouse Model of Dry Eye

et al. 2021

View full text Add to dashboard Cite

Purpose: To elucidate the expression profile and the potential role of long non-coding ribonucleic acids (RNAs) (lncRNAs) in a dry eye disease (DED) model.Methods: A DED model was established in C57BL/6J mice with 0.2% benzalkonium chloride (BAC) twice a day for 14 days. The differentially expressed lncRNAs were detected by RNA-seq technology (Gene Expression Omnibus, GEO GSE186450) and the aberrantly expressed lncRNAs were further verified by RT-qPCR. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were conducted to predicate the related candidate genes and potential pathological pathways. Cells from a human corneal epithelial cell line (HCECs) were cultured under hyperosmolarity. The regulation of inflammatory factors by silencing potential targeted lncRNAs was verified in vitro in HCECs.Results: In our study, a significant increase in corneal fluorescence staining and a reduction in tear production were observed in DED mice at all follow-ups compared with the controls, and the differences were increasing over time. In total, 2,649 upregulated and 704 downregulated lncRNAs were identified in DED mice. We selected six aberrantly expressed and most abundant lncRNAs and performed RT-qPCR using the samples for RNA-seq. Chrnb2, Gabarapl2, and Usp31 were thereby confirmed as the most significantly altered lncRNAs. Pathway analysis revealed that the neuroactive ligand–receptor interaction signaling pathway was the most enriched, followed by the calcium signaling pathway and cytokine–cytokine receptor interaction. Following treatment of Gabarapl2 siRNA and Chrnb2 siRNA, tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, and IL-6 were significantly downregulated in the HCECs.Conclusion: Our study suggests that Chrnb2 and Gabarapl2 may be involved in the inflammation response by regulating TNF-α, IL-1β, and IL-6 in DED. These candidate lncRNAs may be both potential biomarkers and therapeutic targets for DED.

show abstract

Long non-coding RNA TINCR as potential biomarker and therapeutic target for cancer

Cited by 54 publications

References 87 publications

Long Non-Coding RNAs as Potential Diagnostic and Prognostic Biomarkers in Breast Cancer: Progress and Prospects

Long Non-Coding RNAs as Potential Diagnostic and Prognostic Biomarkers in Breast Cancer: Progress and Prospects

MicroRNAs and Long Noncoding RNAs as Novel Therapeutic Targets in Estrogen Receptor-Positive Breast and Ovarian Cancers

Long Non-coding RNAs Gabarapl2 and Chrnb2 Positively Regulate Inflammatory Signaling in a Mouse Model of Dry Eye

Contact Info

Product

Resources

About